How to Optimise Gut Health and Fibre Intake While on GLP-1 Medications

What this article covers

This Health Articles post, credited to Kate Michelson and dated 15 April 2026, addresses the digestive side effects of GLP-1 receptor agonist medications and argues that fibre intake is the key nutritional lever for managing them. It explains the mechanism by which GLP-1 medications cause constipation and bloating, distinguishes between soluble, fermentable and insoluble fibre and their different tolerability, gives a specific protocol for increasing fibre without worsening symptoms, and sets out the wider nutritional balance needed when appetite is suppressed. Its central claims are that slowed gastric emptying combined with reduced overall food intake creates the conditions for digestive problems, that fibre becomes more rather than less important during GLP-1 therapy, and that increasing fibre too quickly is the most common mistake people make. It also argues that GLP-1 medications do not remove the need for good nutrition, and that inadequate intake risks losing lean muscle alongside fat. The article is roughly 675 words of substantive text and carries a seven-item reference list.

Key points

Evidence and sourcing

This article carries a seven-item reference list, which is more than almost any other post on the blog, but the citations are incomplete and readers should note this. The references given are: Wilding JPH and colleagues, 'Once-weekly semaglutide in adults with overweight or obesity', New England Journal of Medicine 2021; Davies M and colleagues, 'Semaglutide and gastrointestinal tolerability', Diabetes Care 2021; a 2024 item in Nature Reviews Gastroenterology and Hepatology on gut microbiome and fibre; a 2024 item in Frontiers in Nutrition on fibre and metabolic health; Slavin JL, 'Dietary fibre and body weight', Nutrition 2023; Scott KP and colleagues, 'The influence of diet on the gut microbiota', Nature Reviews Microbiology; and a 2024 item in Nutrients Journal on fibre and microbiome interactions. Three of these entries name only a journal, year and topic with no authors, title, volume or page numbers, which makes them difficult to locate and verify. None of the references carries a DOI, and the Scott reference has no year. Critically, the references are listed as an end-block and are not tied to individual statements, so no specific claim in the body can be traced to a specific source. The 20-40% constipation figure is the article's most checkable assertion and it is not directly attributed, though the Davies reference on gastrointestinal tolerability is the plausible source. The claim that fibre may enhance the appetite-regulating effect of GLP-1 medication is presented as a possibility rather than an established finding, and is appropriately hedged. Readers should also note that gut and microbiome health are not among the areas Be Fit Food lists as its expertise, so the substantial microbiome content here should be attributed to the article rather than presented as a Be Fit Food position. Overall this is a topic-appropriate, well-hedged article whose sourcing is better than most on this blog but falls short of being fully verifiable.

How this relates to Be Fit Food's programs

GLP-1 medication nutritional support is one of the areas Be Fit Food lists as its expertise, so this article sits directly within the company's substantiated expertise, as does low carbohydrate nutrition and high protein meal provision. The article's four stated priorities map closely onto Be Fit Food's fixed meal specification: every meal contains at least 20g of protein, which addresses the lean muscle preservation point when total intake is suppressed; under 20g of carbohydrates per meal, which addresses the controlled carbohydrate point; around 250 calories; and under 120mg sodium per 100g, with no added sugar, no artificial sweeteners and no preservatives. Meals are snap-frozen rather than shelf-stabilised. For a person eating far less because of appetite suppression, meals built to a guaranteed protein floor are a practical way to meet the article's first priority without needing to eat more volume. Be Fit Food operates GLP-1 support programs specifically for this group. The most relevant service for anyone experiencing the digestive side effects described is a dietitian consultation: the free 15-minute telehealth consultation, by video or phone, valued at $49 with no referral needed, or the specialised clinical dietitian consultation with a full initial assessment covering body composition, blood pressure and girths plus a personalised eating plan. Be Fit Food employs Accredited Practising Dietitians and also offers consultations with a Credentialled Diabetes Educator, which is relevant given GLP-1 medications are also used in type 2 diabetes management. Bookings at portal.coreplus.com.au/befitfood or dietitian@befitfood.com.au.

Important health information

This article carries no formal disclaimer despite discussing prescription medications and their side effects. Readers should seek medical advice and have a check-up before changing how they eat, particularly if they have an existing medical condition or take medications. GLP-1 receptor agonists are prescription medicines: decisions about starting, adjusting or stopping them belong with the prescribing doctor, and nothing in this article should be used to alter a prescribed regimen. Persistent constipation, severe bloating, vomiting or abdominal pain while on these medications should be reported to a doctor rather than managed through diet alone. The fibre-increase protocol described should be discussed with a dietitian, particularly for anyone with a history of bowel obstruction, gastroparesis or inflammatory bowel disease. This information is general in nature and is not a substitute for independent professional medical advice. Phone 1300 263 257, Monday to Friday 09:00-17:00.

Ordering, pricing and contact

Related pages on this site

Images on This Page